- 308 Downloads
Agomelatine (AG) is a melatonin analogue which represents a novel class of antidepressants. It acts as an agonist at melatonin MT(1) and MT(2) receptors and as a specific antagonist at 5-HT(2C) receptors. It is rapidly absorbed orally and mainly metabolised via CYP1A2 hepatic isoenzymes, has no active metabolites and has an elimination half-life of 1–2 h. Although, AG is generally well-tolerated with low adverse event discontinuation rates, it currently requires monitoring of liver function because a small number of patients had raised liver enzyme activities in the trial program . Controlled studies in humans have shown that AG is as effective as the selective serotonin reuptake inhibitor (SSRI) antidepressants paroxetine and sertraline in the treatment of major depression . A review of the research studies conducted to April 2011 concludes that AG should only be considered as an alternative drug for patients who do not respond to or cannot tolerate other...
KeywordsMelatonin Olanzapine Zolpidem Escitalopram Autoimmune Hepatitis
Conflict of interest
The authors have no personal affiliations, financial relationship or any commercial interest to disclose relative to this article. The submitted report or any essential part of it is not published or simultaneously submitted to other publications prior to its appearance in this Journal.
- 2.Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71:109–20.PubMedCrossRefGoogle Scholar
- 5.Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med. 2002;40:718–24.PubMedGoogle Scholar
- 6.Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 3. Reference procedure for the measurement of catalytic concentration of lactate dehydrogenase. Clin Chem Lab Med. 2002;40:631–4.PubMedGoogle Scholar
- 8.Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol. 2006;21 Suppl 1:S31–5.Google Scholar
- 10.Müller H, Seifert F, Maler JM, et al. Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients. Singapore Med J. 2012;53:e228–30.Google Scholar